Relmada Therapeutics (RLMD) Tops Q4 EPS by 3c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($1.80), $0.03 better than the analyst estimate of ($1.83).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Nebius soars on second quarter revenue beat
• Avino Silver & Gold Mines (ASM) Misses Q2 EPS by 4c
• Fervo Energy Company (FRVO) Reports Q2 Loss of $0.38